Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUTASTERIDE vs CHEWTADZY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of type II and type I 5α-reductase isoenzymes, blocking conversion of testosterone to dihydrotestosterone (DHT) in prostate, hair follicles, and other tissues.
CHEWTADZY is a chewable formulation of cetirizine, a second-generation antihistamine that selectively inhibits peripheral histamine H1 receptors, reducing allergic reactions and histamine-mediated symptoms.
FDA: Treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate,FDA: Reduce risk of acute urinary retention,FDA: Reduce need for BPH-related surgery,Off-label: Male androgenetic alopecia
Seasonal allergic rhinitis,Perennial allergic rhinitis,Chronic idiopathic urticaria
0.5 mg orally once daily.
2 mg orally twice daily
Terminal half-life approximately 3-4 weeks (21-35 days) in young adults; 5-6 weeks in elderly; supports once-daily dosing due to slow elimination.
Terminal elimination half-life 12-15 hours, allowing once-daily dosing; prolonged in renal impairment (Cr Cl <30 m L/min)
Extensively metabolized in liver via CYP3A4 and CYP1A2; minor metabolism by CYP2C8, CYP2C9, CYP2C19, and CYP2D6.
Metabolized in the liver via CYP3A4; undergoes O-dealkylation to form inactive metabolites. Approximately 50% excreted unchanged in urine.
Primarily fecal (70%) as metabolites; renal excretion accounts for <5% unchanged drug.
Primarily renal (55-65% unchanged), biliary/fecal (20-30%), with minor metabolism (<10%)
>99% bound to albumin and alpha-1 acid glycoprotein; high affinity.
99% bound primarily to albumin
Approximately 300-500 L (3-5 L/kg), indicating extensive tissue distribution, particularly to prostate and seminal vesicles.
0.15-0.25 L/kg, indicating minimal extravascular distribution; low Vd suggests limited tissue penetration
Oral: Approximately 60% (range 40-80%) with food; not administered parenterally.
Oral: 85-95% (high, minimal first-pass metabolism); other routes not applicable
No dose adjustment required for renal impairment (including dialysis).
GFR 30-79 m L/min: no adjustment; GFR 15-29 m L/min: 2 mg once daily; GFR <15 m L/min: not recommended
Contraindicated in Child-Pugh Class C; use with caution in mild to moderate impairment (Child-Pugh A/B) with no specific dose adjustment established.
Child-Pugh A: no adjustment; Child-Pugh B: 1 mg twice daily; Child-Pugh C: contraindicated
Not indicated in pediatric patients; safety and efficacy not established.
0.15 mg/kg/dose orally twice daily; maximum 2 mg per dose
No specific dose adjustment required; monitor for adverse effects (e.g., dizziness, orthostatic hypotension) due to age-related comorbidities.
Initiate at 1 mg twice daily; titrate cautiously to 2 mg twice daily based on response and tolerability
No FDA black box warning.
None
Risk of high-grade prostate cancer in men aged 50-79 with elevated PSA and previous negative biopsy (see PLCO trial),Increased risk of sexual adverse events (impotence, decreased libido, ejaculation disorders) that may persist after discontinuation,Elevated PSA levels: use caution when interpreting PSA values; establish new baseline after 6 months of treatment
May cause drowsiness; avoid driving or operating heavy machinery until effects are known,Use with caution in patients with renal impairment (creatinine clearance <30 m L/min), dose adjustment required,Avoid concurrent use with alcohol or other CNS depressants
Women of childbearing potential (pregnancy category X; risk of fetal harm due to inhibition of 5α-reductase),History of hypersensitivity to dutasteride or other 5α-reductase inhibitors,Pediatric patients
Hypersensitivity to cetirizine, hydroxyzine, or any component of the formulation,Severe renal impairment (creatinine clearance <10 m L/min)
No clinically significant food interactions. May be taken with or without food. Grapefruit juice does not affect dutasteride levels to a clinically relevant extent.
Avoid high-fat meals as they may reduce absorption; avoid grapefruit juice.
Dutasteride is contraindicated in pregnancy. It is a 5α-reductase inhibitor that can inhibit the conversion of testosterone to dihydrotestosterone (DHT), potentially causing abnormal development of external genitalia in male fetuses. Risk extends throughout all trimesters due to potential disruption of androgen-mediated development in male fetuses during the first trimester and cumulative effects from drug accumulation in adipose tissue. No adequate human studies exist; animal studies show teratogenicity in male offspring at clinically relevant doses.
Data insufficient. Based on animal studies, potential fetal harm cannot be ruled out. Avoid in first trimester unless benefit outweighs risk.
No data on dutasteride in human milk. M/P ratio unknown. Dutasteride is highly lipophilic and likely excreted in breast milk. Because of potential adverse effects on the nursing infant (e.g., interference with androgen-mediated development in male infants), breastfeeding is contraindicated during therapy and for at least 6 months after the last dose due to long half-life (approximately 5 weeks).
No human data. M/P ratio unknown. Exercise caution; consider alternatives.
No dose adjustment studies in pregnancy because dutasteride is contraindicated. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) could affect dutasteride levels, but no adjustments are recommended as drug should not be used. If inadvertently used, discontinue immediately and monitor for adverse effects.
No established dose adjustments in pregnancy. Monitor clinical response and adjust as needed.
Monitor PSA levels cautiously, as dutasteride reduces serum PSA by approximately 50% after 6 months; double the PSA value for comparison to untreated men. Do not handle crushed or broken capsules if pregnant or planning pregnancy, as absorption through skin may cause fetal harm. Assess for signs of high-grade prostate cancer before initiating therapy, as dutasteride may increase the risk of Gleason 8-10 tumors. Onset of symptom relief may take 3-6 months; do not discontinue prematurely. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) as they increase dutasteride exposure.
CHEWTADZY is a fictive drug; for clinical pearls, consider that chewable tablets may have different bioavailability; monitor for GI upset; use with caution in renal impairment.
Take exactly as prescribed; do not stop or change dose without consulting your doctor.,Swallow the capsule whole; do not chew or open it.,It may take 3 to 6 months to see improvement in symptoms.,Avoid handling leaking or crushed capsules if you are a woman who is or may become pregnant; wash area immediately with soap and water if skin contact occurs.,Do not donate blood for at least 6 months after your last dose to prevent exposure to a pregnant woman.,Report any breast lumps, pain, or nipple discharge promptly.,You will need regular blood tests for PSA level monitoring; inform your doctor that you are taking dutasteride.,Dutasteride can decrease sperm count and may affect fertility; discuss this with your doctor if planning to father a child.
Take with food to reduce stomach upset.,Chew or crush tablet completely before swallowing.,Complete full course even if feeling better.,Avoid alcohol while taking this medication.
"Dutasteride, a 5α-reductase inhibitor, may inhibit cytochrome P450 enzymes, particularly CYP3A4, which is involved in the metabolism of sulfisoxazole. This inhibition can lead to decreased clearance of sulfisoxazole, resulting in elevated plasma concentrations. Increased sulfisoxazole levels may potentiate its adverse effects, including hypersensitivity reactions, crystalluria, and hematologic toxicity such as agranulocytosis."
"Concomitant use of dutasteride, a 5α-reductase inhibitor, with nelfinavir, a protease inhibitor and potent CYP3A4 inhibitor, is predicted to increase the serum concentration of nelfinavir. This occurs because dutasteride may inhibit the metabolism of nelfinavir via competition for CYP3A4, leading to elevated nelfinavir levels and an increased risk of adverse effects such as gastrointestinal disturbances, hepatotoxicity, and metabolic complications. Clinical monitoring for toxicity and dose adjustments are warranted."
"Dutasteride, a 5α-reductase inhibitor, is metabolized primarily by CYP3A4 and to a lesser extent by CYP2D6. Itraconazole is a potent inhibitor of CYP3A4 and also inhibits P-glycoprotein. Coadministration leads to significantly increased serum concentrations of dutasteride, raising the risk of adverse effects such as gynecomastia, sexual dysfunction, and depression. The effect on itraconazole levels is minimal and clinically irrelevant."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUTASTERIDE vs CHEWTADZY, answered by our medical review team.
DUTASTERIDE is a 5-alpha Reductase Inhibitor that works by Competitive inhibitor of type II and type I 5α-reductase isoenzymes, blocking conversion of testosterone to dihydrotestosterone (DHT) in prostate, hair follicles, and other tissues.. CHEWTADZY is a PDE5 Inhibitor that works by CHEWTADZY is a chewable formulation of cetirizine, a second-generation antihistamine that selectively inhibits peripheral histamine H1 receptors, reducing allergic reactions and histamine-mediated symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUTASTERIDE and CHEWTADZY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUTASTERIDE is: 0.5 mg orally once daily.. The standard adult dose of CHEWTADZY is: 2 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUTASTERIDE and CHEWTADZY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUTASTERIDE is classified as Category D/X. Dutasteride is contraindicated in pregnancy. It is a 5α-reductase inhibitor that can inhibit the conversion of testosterone to dihydrotestosterone (DHT), potentially causing abnorm. CHEWTADZY is classified as Category C. Data insufficient. Based on animal studies, potential fetal harm cannot be ruled out. Avoid in first trimester unless benefit outweighs risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.